glp-1 vs insulin Schematic of action of on secretion GLP-1 vs. GLP-1 + GIP:

Notably, lixisenatide users had the highest risk, with a hazard ratio of 2.002 (95% CI: 1.3023.079) compared to DPP-4i users

In IBD, the increased production of NO, coupled with excessO2, results in elevated ONOO-levels

Oussalah, Abderrahim, et al

Retrieved February 27, 2025

Deeper into the gastrointestinal angle, a truncated glucagon-like peptide (GLP-1 or incretin) is secreted by endocrine L cells of the lower intestine after meal or glucose ingestion

[33] Based on the clinical dosing regimen (2.5 to 5 mg TZP weekly), we estimated that a depot designed to release TZP continuously over four months in a rat model should contain approximately 4.5 mg of drug within a subcutaneously injectable volume (typically 0.5 to 2 mL)